RESUMO
The purpose of this study was to determine whether 5-fluorouracil administered as a single intraoperative dose beneath the conjunctival flap during trabeculectomy in patients with glaucoma would be safe and effective. This prospective case series consists of 43 eyes of 43 consecutive patients who underwent trabeculectomy with intraoperative topical administration of 5-fluorouracil. Surgical outcome and success rate of the procedure were evaluated at a 6-month follow-up period. Success was defined as a postoperative intraocular pressure (IOP) of =21 mm Hg with a minimum 20% drop in IOP from preoperative levels and one Snellen line or less loss of visual acuity, at the end of 6 months. The overall success rate was 85.4%. Mean IOP was 31.4 +/- 11.4 preoperatively and 15.1 +/- 4.6 postoperatively. The mean number of antiglaucoma medications was reduced from 2.8 +/- 0.9 to 0.4 +/- 0.7. Success rates were 69.2% in eyes with high risk for failure and 92.9% in relatively low-risk eyes. A thin and ischemic bleb was characteristic in the immediate postoperative period and remained so in all successful eyes with the exception of five eyes (11.6%) that developed encapsulated blebs. There were no corneal epithelial complications. Intraoperative 5-fluorouracil application directly to the trabeculectomy site appears to be a safe and effective method. It can be a valuable alternative in glaucoma surgery, but may be less successful in eyes with high risk for failure.
RESUMO
PURPOSE: This study was to determine the role of changes in refractive error, contrast sensitivity, and corneal topography in transient changes in visual function following trabeculectomy. METHODS: We performed a prospective study evaluating these factors in 13 consecutive patients undergoing a standardized trabeculectomy. Preoperatively, and at 1, 4, and 12 weeks postoperatively, we measured best-corrected visual acuity, refractive error, and contrast sensitivity and analyzed computerized video-keratographic studies including estimated corneal visual acuity. RESULTS: One week postoperatively, best-corrected visual acuity decreased at least one line in 8 of 13 patients, whereas no eyes had decreased contrast sensitivity. Mean central corneal astigmatism increased 1.4 diopters along the surgical meridian. By 12 weeks, visual acuity returned to preoperative levels in all patients and the corneal topographic changes returned to within 1 diopter of preoperative values in 12 of 13 patients. Postoperative changes in estimated corneal visual acuity were similar to those in best-corrected visual acuity with no statistically significant difference. CONCLUSIONS: Corneal topographic changes appear to contribute to visual acuity reduction following trabeculectomy. In most cases this is transient with return to preoperative topography within 12 weeks.
Assuntos
Sensibilidades de Contraste/fisiologia , Córnea/patologia , Glaucoma/fisiopatologia , Erros de Refração/fisiopatologia , Trabeculectomia , Acuidade Visual/fisiologia , Idoso , Córnea/fisiopatologia , Feminino , Seguimentos , Glaucoma/cirurgia , Humanos , Processamento de Imagem Assistida por Computador , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Erros de Refração/etiologiaRESUMO
We report the preliminary results of the first 20 consecutive cases in which the antimetabolite 5-fluorouracil (5-FU) was applied directly beneath the conjunctival flap during trabeculectomy in high-risk patients. Seventeen were considered early successes, with 3-month postoperative intraocular pressures less than 21 mmHg, representing at least a 20% decrease from preoperative values. Successful blebs were pale, with conjunctival microcysts and without significant vascularization over the trabeculectomy site, similar to the appearance of blebs in eyes administered postoperative subconjunctival injections of 5-FU. There were no cases of corneal epithelial defects, and no eyes had lost more than one line of preoperative vision at the time of last follow up. Although the longer term efficacy of this method is unknown, these results suggest that it may represent a safe and effective alternative for administering 5-FU.